# Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)

> **NCT03242928** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 68 (actual)

## Conditions studied

- Cocaine-related Disorder

## Interventions

- **DRUG:** AFQ056
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03242928
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-04
- **Primary completion:** 2019-12-16
- **Final completion:** 2019-12-16
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03242928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03242928, "Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03242928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*